All Butantan Institute articles
-
NewsDengue vaccine remains 80.5% effective against severe cases after five years
The tetravalent dengue vaccine was 80.5% effective against severe dengue cases with warning signs over a five-year period. Overall, the vaccine was 65% effective in preventing symptomatic dengue (caused by any serotype) during the five years of monitoring.
-
NewsCompound derived from Brazilian plant acts against parasite that causes visceral leishmaniasis
A compound derived from Nectandra leucantha, a tree native to southern Brazil (local names canela-seca or canela-branca), has the potential to be used to treat visceral leishmaniasis, a neglected tropical disease.
-
NewsResearchers reveals why recombinant BCG induces a stronger and longer-lasting response
Researchers are working on a more potent version of the BCG vaccine that protects against TB. While the conventional immunizer reduced infection by 90% in experiments with mice, the recombinant BCG increased protection rates to 99%.
-
NewsDengue vaccine protects 79.6% of those vaccinated, study shows
The single-dose Butantan-DV dengue vaccine prevents development of the disease in 79.6% of those vaccinated, according to a new study.